X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale+OE | $15.62 | -2,615 | 108,739 | -2% | -$40,840 | |||||
| D | 2024-02-16 | DCPH | Kelly Thomas Patrick | CFO | S - Sale+OE | $15.62 | -3,010 | 80,350 | -4% | -$47,009 | |||||
| D | 2024-02-16 | DCPH | Pitman Jama | SVP, Chief Development Officer | S - Sale+OE | $15.62 | -2,267 | 68,031 | -3% | -$35,405 | |||||
| D | 2024-02-16 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale+OE | $15.62 | -2,267 | 55,118 | -4% | -$35,405 | |||||
2024-01-16 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $14.47 | -2,435 | 94,079 | -3% | -$35,234 | ||||||
2024-01-16 | DCPH | Pitman Jama | SVP, Chief Development Officer | S - Sale | $14.47 | -1,624 | 50,573 | -3% | -$23,499 | ||||||
2024-01-16 | DCPH | Kelly Thomas Patrick | CFO | S - Sale | $14.47 | -2,435 | 66,085 | -4% | -$35,234 | ||||||
2024-01-16 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale | $14.47 | -1,624 | 47,660 | -3% | -$23,499 | ||||||
2023-12-13 | DCPH | Hoerter Steven L. | Pres, CEO | S - Sale | $15.37 | -30,664 | 72,763 | -30% | -$471,217 | ||||||
2023-12-13 | DCPH | Kelly Thomas Patrick | CFO | S - Sale | $15.37 | -2,792 | 68,520 | -4% | -$42,905 | ||||||
2023-12-13 | DCPH | Pitman Jama | See Remarks | S - Sale | $15.37 | -1,662 | 52,197 | -3% | -$25,540 | ||||||
2023-12-13 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale | $15.37 | -1,727 | 49,284 | -3% | -$26,539 | ||||||
2023-12-13 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $15.37 | -2,792 | 96,514 | -3% | -$42,905 | ||||||
2023-11-30 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale | $12.57 | -17,801 | 45,435 | -28% | -$223,755 | ||||||
2023-10-30 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $12.02 | -2,360 | 90,628 | -3% | -$28,362 | ||||||
2023-10-30 | DCPH | Pitman Jama | See Remarks | S - Sale | $12.02 | -1,407 | 48,283 | -3% | -$16,909 | ||||||
2023-10-30 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale | $12.02 | -1,407 | 62,884 | -2% | -$16,909 | ||||||
2023-10-30 | DCPH | Kelly Thomas Patrick | CFO | S - Sale | $12.02 | -2,316 | 63,068 | -4% | -$27,833 | ||||||
2023-10-30 | DCPH | Hoerter Steven L. | Pres, CEO | S - Sale | $12.02 | -21,573 | 40,927 | -35% | -$259,256 | ||||||
2023-10-02 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $12.68 | -2,942 | 84,744 | -3% | -$37,305 | ||||||
2023-06-16 | DCPH | Pitman Jama | See Remarks | S - Sale | $14.40 | -1,238 | 43,812 | -3% | -$17,829 | ||||||
2023-06-16 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $14.40 | -1,655 | 87,686 | -2% | -$23,835 | ||||||
2023-06-16 | DCPH | Kelly Thomas Patrick | CFO | S - Sale | $14.40 | -1,655 | 57,140 | -3% | -$23,835 | ||||||
2023-06-16 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale | $14.40 | -1,238 | 58,413 | -2% | -$17,829 | ||||||
2023-06-16 | DCPH | Flynn Daniel Lee | Chief Scientific Officer | S - Sale | $14.40 | -1,655 | 378,613 | 0% | -$23,835 | ||||||
2023-06-08 | DCPH | Friedman Franklin Stuart | Dir | P - Purchase | $13.88 | +10,000 | 10,000 | New | +$138,828 | ||||||
2023-05-10 | DCPH | Walsh Dennis Leo | Dir | P - Purchase | $13.86 | +11,000 | 11,000 | New | +$152,416 | ||||||
2023-03-21 | DCPH | Hoerter Steven L. | Pres, CEO | S - Sale | $15.57 | -7,500 | 0 | -100% | -$116,782 | ||||||
| D | 2023-02-16 | DCPH | Pitman Jama | See Remarks | S - Sale+OE | $15.10 | -1,159 | 45,050 | -3% | -$17,500 | |||||
| D | 2023-02-16 | DCPH | Martin Daniel C. | Chief Commercial Officer | S - Sale+OE | $15.10 | -1,159 | 58,381 | -2% | -$17,500 | |||||
| D | 2023-02-16 | DCPH | Kelly Thomas Patrick | CFO | S - Sale+OE | $15.10 | -1,370 | 58,795 | -2% | -$20,686 | |||||
| D | 2023-02-16 | DCPH | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale+OE | $15.10 | -971 | 88,145 | -1% | -$14,661 | |||||
| D | 2023-02-16 | DCPH | Flynn Daniel Lee | Chief Scientific Officer | S - Sale+OE | $15.10 | -1,370 | 380,268 | 0% | -$20,686 | |||||
| D | 2023-02-14 | DCPH | Hoerter Steven L. | Pres, CEO | S - Sale+OE | $16.00 | -30,045 | 7,500 | -80% | -$480,720 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |